Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 13

1.

Costs associated with febrile neutropenia in the US.

Michels SL, Barron RL, Reynolds MW, Smoyer Tomic K, Yu J, Lyman GH.

Pharmacoeconomics. 2012 Sep 1;30(9):809-23. doi: 10.2165/11592980-000000000-00000.

PMID:
22804805
2.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
3.

Economic burden of haematological adverse effects in cancer patients: a systematic review.

Liou SY, Stephens JM, Carpiuc KT, Feng W, Botteman MF, Hay JW.

Clin Drug Investig. 2007;27(6):381-96. Review.

PMID:
17506589
4.

The timing of chemotherapy-induced neutropenia and its clinical and economic impact.

Ozer H.

Oncology (Williston Park). 2006 Apr;20(5 Suppl 4):11-5. Review.

5.

Economic burden of chemotherapy-induced febrile neutropenia in patients with lymphoma: a systematic review.

Wang XJ, Lopez SE, Chan A.

Crit Rev Oncol Hematol. 2015 May;94(2):201-12. doi: 10.1016/j.critrevonc.2014.12.011. Epub 2014 Dec 31. Review.

PMID:
25600838
6.

Chemotherapy dose intensity and quality cancer care.

Lyman GH.

Oncology (Williston Park). 2006 Dec;20(14 Suppl 9):16-25. Review.

7.

Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review.

Lyman GH, Abella E, Pettengell R.

Crit Rev Oncol Hematol. 2014 Jun;90(3):190-9. doi: 10.1016/j.critrevonc.2013.12.006. Epub 2013 Dec 12. Review.

PMID:
24434034
8.

Outpatient management of febrile neutropenia associated with cancer chemotherapy: risk stratification and treatment review.

Pherwani N, Ghayad JM, Holle LM, Karpiuk EL.

Am J Health Syst Pharm. 2015 Apr 15;72(8):619-31. doi: 10.2146/ajhp140194. Review.

PMID:
25825185
9.

Outpatient Benzodiazepine Prescribing, Adverse Events, and Costs.

French DD, Spehar AM, Campbell RR, Palacios P, Coakley RW, Coblio N, Means H, Werner DC, Angaran DM.

In: Henriksen K, Battles JB, Marks ES, Lewin DI, editors. Advances in Patient Safety: From Research to Implementation (Volume 1: Research Findings). Rockville (MD): Agency for Healthcare Research and Quality (US); 2005 Feb.

10.

Febrile neutropenia in children treated for malignancy.

Barton CD, Waugh LK, Nielsen MJ, Paulus S.

J Infect. 2015 Jun;71 Suppl 1:S27-35. doi: 10.1016/j.jinf.2015.04.026. Epub 2015 Apr 25. Review.

PMID:
25917801
11.

What Happens After a Patient Safety Event? Medical Expenditures and Outcomes in Medicare.

Encinosa WE, Hellinger FJ.

In: Henriksen K, Battles JB, Marks ES, Lewin DI, editors. Advances in Patient Safety: From Research to Implementation (Volume 1: Research Findings). Rockville (MD): Agency for Healthcare Research and Quality (US); 2005 Feb.

12.

Management of febrile neutropenia in pediatric oncology across Queensland, Australia: a retrospective review on variations between locations.

Cox A, Bradford N.

J Pediatr Oncol Nurs. 2014 Jan-Feb;31(1):28-33. doi: 10.1177/1043454213514793. Epub 2013 Dec 30. Review.

PMID:
24378817
13.

Bending the Cost Curve in Childhood Cancer.

Russell H, Bernhardt MB.

Curr Hematol Malig Rep. 2016 Aug;11(4):295-302. doi: 10.1007/s11899-016-0332-3. Review.

PMID:
27193602
Items per page

Supplemental Content

Write to the Help Desk